You just read:

ActoBio Therapeutics™ Progresses AG019 to Next Stage of a Phase Ib/IIa Clinical Study for the Treatment of Type 1 Diabetes

News provided by

ActoBio Therapeutics, Inc.

Jul 01, 2019, 07:30 ET